Navigation Links
First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
Date:8/27/2007

hen used in combination with the chemotherapy drug, carboplatin. Ovarian cancer patients whose cancer initially responded to chemotherapy, but has since become resistant or refractory to traditional platinum treatments are eligible to participate.

There will be an additional 30 sites in the USA, of which 7 are now recruiting patients, and there are 4 sites open in Australia.

The total number of patients to be treated in this pivotal study is 470. The trial consists of two double blind treatment arms. Patients in one trial arm will receive weekly carboplatin and phenoxodiol. Patients in the other trial arm will also receive weekly carboplatin, but a placebo will be substituted for phenoxodiol. Neither patients, nor their doctors will know to which trial arm the patients are randomised.

A change from receiving carboplatin (or cisplatin) in the traditional dose pattern (every two to three weeks) to a weekly carboplatin regimen has been reported to provide a tumour response in some patients with recurrent ovarian cancer(1-3). Thus in addition to learning more about the safety and efficacy of phenoxodiol, researchers will learn more about the efficacy of weekly carboplatin.

The primary outcome of the trial is the assessment of the relative time it takes for the ovarian cancer to progress. An analysis of interim results will be possible after 95 patients have progressed with their disease.

The trial is being run under arrangements approved by the US Food and Drug Administration (FDA) known as a Special Protocol Assessment (SPA). This provides for the interim analysis of the data, which, if significant, can be used to support a request for grant of marketing approval.

The Chief Executive Officer of Marshall Edwards, Inc., Mr. Christopher Naughton, said the Phase III Ovature study was a significant milestone for the Company.

"Over the next 12 to 18 months we expect the interim results from this multi-national clinical trial which ma
'/>"/>

SOURCE Novogen Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014" ... conventional methods developed to prevent and eradicate the prevalence ... These methods are confined to low specificity, safety and ... to look for a better solution. It has been ...
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- ChemImage will present a workshop focused ... Zealand Forensic Science Society,s 22 nd International ... Adelaide, Australia .  Forensic Scientists will be ... hyperspectral imaging can bring to examination procedures. ... of Product Development at ChemImage, will host a ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
(Date:8/30/2014)... Tenn. (PRWEB) August 30, 2014 ... around the country for the past several years, ... Tennessee Hyperbaric Center have announced a scholarship program ... This announcement follows a meeting held this summer ... In recent years, reporters have shed light on ...
(Date:8/30/2014)... VA (PRWEB) August 30, 2014 Seniors Guide, ... articles recently that focus on Alzheimer’s Disease, Dementia, and ... revealed to the public of being diagnosed with the Alzheimer’s, ... latest movie, “I’ll Be Me”. The movie, out on ... while focusing on his diagnosis of the disease – which ...
(Date:8/30/2014)... 2014 Continuing to meet the skin ... with the addition of a new doctor and office ... provided leading-edge skin care in Grand Rapids since 1980 ... “As a doctor, my passion is making sure my ... Forefront Dermatology, I’m better able to focus on my ...
(Date:8/30/2014)... Hastings and Hastings, a qualified team ... Arizona is pleased to report having saved a client ... among many cases where Hastings and Hastings has tailored ... a greater portion of their settlement or recovery. The ... positive solution for Arizona car accident victims is achievable ...
(Date:8/30/2014)... 30, 2014 Market Research Report ... is a professional and in-depth market survey on ... firstly reviews the basic information of Lab Oven ... report then explores global and China’s top manufacturers ... production value, and market share etc. , The ...
Breaking Medicine News(10 mins):Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:Expanding Care at the Forefront of Dermatology 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4
... , CINCINNATI, July 21 ... provider of physician office-based patient-education programs, announces the launch ... delivers real-time health content to physicians all day, every ... back office, medical news and information is sourced from ...
... the mechanics of how two types of white blood cells ... models that are used to predict how immune system cells ... Professor Phil Hodgkin, head of the institute,s Immunology Division, is ... white blood cells that are crucial to the body,s ...
... , , , OKLAHOMA ... a "D" to a "B" grade in the 2009 National Alliance on Mental ... of the nation,s public mental health care system.(1) Oklahoma showed the greatest improvement ... , , Oklahoma,s report card ...
... , BEAVERTON, Ore., July 21 ... today announced Breach Prevent for Healthcare, a customizable set of ... comply with the new HITECH Act privacy regulations. ... expands HIPAA,s privacy rules with specific data breach notification requirements ...
... , , , ... INIS) is pleased to announce the results of its annual shareholder meeting ... advancing its plans for the construction of a depleted uranium de-conversion ... , , The Company,s annual meeting was ...
... , DOYLESTOWN, Pa., July 21 ... have entered into an agreement for LaRon to co-promote Avidas, ... DK defence kit. Under the terms of the agreement, LaRon ... medicine physicians in the United States, while Avidas will continue ...
Cached Medicine News:Health News:Healthy Advice Networks Announces the Launch of PracticeWire; Technology to Deliver Real-time Healthcare Content to Physicians 2Health News:Cell division find prompts overhaul of immune response modeling 2Health News:National Report Ranks Oklahoma as a Top State for Mental Health Services 2Health News:National Report Ranks Oklahoma as a Top State for Mental Health Services 3Health News:National Report Ranks Oklahoma as a Top State for Mental Health Services 4Health News:National Report Ranks Oklahoma as a Top State for Mental Health Services 5Health News:National Report Ranks Oklahoma as a Top State for Mental Health Services 6Health News:ID Experts Offers Breach Prevent for Healthcare: A High-Touch, Affordable Solution for HITECH Data Breach Protection and Compliance 2Health News:ID Experts Offers Breach Prevent for Healthcare: A High-Touch, Affordable Solution for HITECH Data Breach Protection and Compliance 3Health News:ID Experts Offers Breach Prevent for Healthcare: A High-Touch, Affordable Solution for HITECH Data Breach Protection and Compliance 4Health News:International Isotopes Inc. Announces Results of the Annual Meeting and Provides an Update on its Depleted Uranium Processing and Fluorine Extraction Process Plant 2Health News:International Isotopes Inc. Announces Results of the Annual Meeting and Provides an Update on its Depleted Uranium Processing and Fluorine Extraction Process Plant 3Health News:International Isotopes Inc. Announces Results of the Annual Meeting and Provides an Update on its Depleted Uranium Processing and Fluorine Extraction Process Plant 4Health News:Avidas(TM) Pharmaceuticals and LaRon(TM) Pharma Inc. Announce Co-Promotion Agreement 2Health News:Avidas(TM) Pharmaceuticals and LaRon(TM) Pharma Inc. Announce Co-Promotion Agreement 3Health News:Avidas(TM) Pharmaceuticals and LaRon(TM) Pharma Inc. Announce Co-Promotion Agreement 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: